Mrinalini Dey DrMiniDey
2 years 2 months ago
POS0592 Increased overall & cause-specific mortality in population-based cohort of people with incident #RA
Higher mortality in RA vs gen pop but this has decreased after 2000 & better 10-year survival
Severe causes of mortality incl cardiac higher in RA
EULAR2024 @RheumNow
Mrinalini Dey DrMiniDey
2 years 2 months ago
POS1035 FVC & risk of lung transplant & mortality in #RAILD
50% pts had FVC % predicted decline in ~6.5yrs
2/3 identified groups more strongly assoc w transplant or ILD-related death than INBUILD definition ➡️marked heterogeneity in ILD progression
#EULAR2024 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 2 months ago
#EULAR2024 POS1245 Healthcare Administrative Data in Italy showed despite prevalence of 3.8/10,000, heathcare cost in #Sjogren was 3 x higher than the general population due to active disease & comorbidities. Call for better MDT approach in management @RheumNow https://t.co/EevoT4jkqr
Peter Nash drpnash
2 years 2 months ago
important session worth reading the full recommendations - TNF tick of approval @RheumNow #EULAR2024 https://t.co/ORDocVie11
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 2 months ago
#EULAR2024 POS1420 A cohort study with 1/3 each with GCA, PMR and GCA+PMR found that at 6mth, 16% of patients had new diabetes/diabetes worsened. Worse in GCA+PMR group with the greatest GC accumulation. Call for better GC-sparing strategy @RheumNow https://t.co/ex7u83bVfj
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 2 months ago
#EULAR2024 POS0742 A single cohort study showed for non-criteria #APS, cardiac manifestation (valvular dysfunction & regurgitation) was more common in Triple Ab+ vs Non-Triple Ab. We should monitor and consider an echocardiogram for this group of patient @RheumNow https://t.co/VxFUSpjaG1
Dr. Antoni Chan synovialjoints
2 years 2 months ago
Active day of learning and discussion with a Round Up from Day 3 of #EULAR2024 with @RheumNow https://t.co/yzLsPNDM5d
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 2 months ago
#EULAR2024 Please find my short blog on the Impact of Safety Warning Update on the use of JAK-inhibitors @RheumNow
https://t.co/Z4pujQRQ9h https://t.co/QRUnJInblH
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 2 months ago
#EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Post-hoc analysis of RCTs + LTE showed Anifrolumab normalised these Haem parameters vs PBO. May improve fatigue-associated with anaemia @RheumNow https://t.co/GF8aKU0Z5x
Dr. John Cush RheumNow
2 years 2 months ago
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies
Despite advancements, some SLE patients remain refractory to belimumab and off-label rituximab, the main B cell-targeted therapies in the last 15 years.
https://t.co/778buNUq1C https://t.co/4ub8VbrLb6
With a better understanding of pathophysiology, improved management guidelines, available medications, and a multidisciplinary approach, pregnancy for lupus patients has become more feasible. Despite these improvements, some patients still experience poor outcomes, highlighting the need for biomarkers that can predict these risks. An abstract presented at #EULAR2024 (POS1393) explored this possibility.
Mrinalini Dey DrMiniDey
2 years 2 months ago
📄 You can now read my article on #CardiovascularDisease, #Stroke & #Mortality @RheumNow!
🌟 Featuring 2 cohort studies from @MayoClinic, presented at #EULAR2024
🔗 https://t.co/b639vE5hSA
@MyasoedovaElena
